Shares of Viking Therapeutics (NASDAQ ... "Our thesis is entirely focused on lead [injectable] drug, VK2735, a GLP-1/GIP dual agonist entering phase 3 development for general obesity." ...

13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ ...

13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily The Phase 2 VENTURE-Oral Dosing Trial is a randomized, double-blind, placebo-controlled multicenter study designed ...

The company plans to initiate Phase 3 development with the subcutaneous formulation of VK2735 in the first half of 2025. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company ...

highlighting the continued enthusiasm for new obesity therapeutics such as VK2735. We look forward to reporting data from this trial in the second half of 2025." Viking previously reported ...

"As with our previous Phase 2 study of subcutaneous VK2735, interest in participating in the Phase 2 VENTURE-Oral study was high and drove an efficient rate of enrollment," said Brian Lian, Ph.D., ...

Brian Lian, Ph.D., CEO of Viking Therapeutics, expressed confidence in CordenPharma’s ability to meet the anticipated significant commercial demand for VK2735 due to their established presence ...

Additionally, the company plans to initiate Phase 3 development with the subcutaneous formulation of VK2735 in the second quarter of 2025. Viking Therapeutics, Inc. is a clinical-stage ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid increasing demand for GLP-1 therapy. Viking Therapeutics has signed a long-term ...